BiotechTube

MDX-1401

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin's Lymphomas

Conditions

Hodgkin's Lymphomas

Trial Timeline

Feb 1, 2008 → Jan 1, 2010

NCT ID
NCT00634452

About MDX-1401

MDX-1401 is a phase 1 stage product being developed by Bristol Myers Squibb for Hodgkin's Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00634452. Target conditions include Hodgkin's Lymphomas.

What happened to similar drugs?

8 of 20 similar drugs in Hodgkin's Lymphomas were approved

Approved (8) Terminated (2) Active (10)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00634452Phase 1Completed

Competing Products

20 competing products in Hodgkin's Lymphomas

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
R-mabHD + ABVDEli LillyPhase 2
31
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21